Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Plus Therapeutics Inc PSTV

Healthcare Biotechnology
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers. The Company combines image-guided local beta radiation and targeted drug delivery approaches. The Company is advancing a pipeline of product candidates with lead programs in recurrent glioblastoma... see more

Recent & Breaking News (NDAQ:PSTV)

Plus Therapeutics Announces Participation at Upcoming SNO Pediatric Conference and SNMMI Annual Meeting

GlobeNewswire June 8, 2023

Plus Therapeutics Provides Company Update Today

GlobeNewswire June 1, 2023

Plus Therapeutics Announces Topline Results from Recurrent Glioblastoma External Control Analysis at ASCO 2023

GlobeNewswire May 30, 2023

Plus Therapeutics to Present at the 2023 Virtual June Investor Summit

GlobeNewswire May 25, 2023

Plus Therapeutics Regains Compliance with Nasdaq Listing Requirements

GlobeNewswire May 16, 2023

Plus Therapeutics to Present in EndBrainCancer Initiative Virtual Educational Event

GlobeNewswire May 12, 2023

Plus Therapeutics Expands Collaboration with Piramal Pharma Solutions to Meet Increase in Investigational Drug Demand for Ongoing and Planned Clinical Trials

GlobeNewswire May 2, 2023

Plus Therapeutics Announces Reverse Stock Split

GlobeNewswire April 28, 2023

Plus Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights

GlobeNewswire April 20, 2023

Plus Therapeutics Completes Enrollment of the Original Three Patients Required for Cohort 8 of ReSPECT-GBM Phase 1/2a Trial

GlobeNewswire April 19, 2023

Plus Therapeutics to Participate in Panel at the Canaccord Genuity Horizons in Oncology Virtual Conference

GlobeNewswire April 18, 2023

Plus Therapeutics Completes Phase 1/Part A of the ReSPECT-LM Clinical Trial for Leptomeningeal Metastases

GlobeNewswire April 18, 2023

Plus Therapeutics to Announce First Quarter 2023 Financial Results and Host Conference Call on April 20, 2023

GlobeNewswire April 12, 2023

Plus Therapeutics Successfully Treats First Patient in Cohort 8 of ReSPECT-GBM Phase 1/2a Trial

GlobeNewswire March 28, 2023

Plus Therapeutics Initiates Cohort 3 in Phase 1/Part A of the ReSPECT-LM Trial for Leptomeningeal Metastases

GlobeNewswire March 22, 2023

Plus Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights

GlobeNewswire February 23, 2023

Plus Therapeutics to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on February 23, 2023

GlobeNewswire February 14, 2023

Plus Therapeutics Completes Enrollment in Second ReSPECT-LM Phase 1 Trial Cohort of Rhenium (¹⁸⁶Re) Obisbemeda for the Treatment of Leptomeningeal Metastases

GlobeNewswire February 1, 2023

Plus Therapeutics Announces First Patient Dosed in ReSPECT-GBM Phase 2b Trial of Rhenium (186Re) Obisbemeda for Treatment of Recurrent Glioblastoma

GlobeNewswire January 18, 2023

Plus Therapeutics Provides Updates on ReSPECT(TM) Clinical Trials at the 27th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology

GlobeNewswire November 19, 2022